[Kineret, Enbrel, Remicade and company. Recombinant drugs in rheumatoid arthritis].
Zündorf
Ilse
I
Johann Wolfgang Goethe-Universität Frankfurt Institut für Pharmazeutische Biologie Marie-Curie-Str. 9 60439 Frankfurt. zuendorf@em.uni-frankfurt.de
Dingermann
Theodor
T
D000068879:Adalimumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000069285:Infliximab; D053590:Interleukin 1 Receptor Antagonist Protein; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012795:Sialoglycoproteins / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; C507763:IL1RN protein, human; D053590:Interleukin 1 Receptor Antagonist Protein; D011994:Recombinant Proteins; D012795:Sialoglycoproteins; D000069285:Infliximab; D000068879:Adalimumab